Manufacture of basic pharmaceutical products and pharmaceutical preparations
Nationally, 1.41% of current registrations have a published bankruptcy opening in the past five years. This sector's historical share is higher than that of 62% of the 88 NACE divisions. The median bankruptcy probability in NACE division 21 is 0.6%, against 0.5% nationally, over 304 scored companies.
Key figures for NACE division 21
fiscal year 2025 · median over 174 filed annual accountsRegional split
by region · 138 of 148 enterprises with a registered office on fileRecent bankruptcies in this sector
2| Date | Company |
|---|---|
| 10-03-2026 | Amalus Therapeutics
BE 0803.929.268 |
| 27-10-2025 | UNIZIMA
BE 0744.643.759 |
Geographic distribution
by province · based on the establishment addressHow these figures are counted
Current enterprise registrations are counted through their registered main activities; establishment units are excluded. Counted in the KBO's NACE 2025 nomenclature, the one in which code 21100 exists.
Share of currently registered companies with a published bankruptcy opening in the past five years. Registered main activities in the selected classification can overlap. This retrospective share is not a future bankruptcy probability.
The comparison with the country and with the other NACE divisions comes from a nightly overview of every division, each counted in the nomenclature in which it exists. A standing such as "higher than 80%" counts the other divisions that have the figure. The bankruptcy probability is the median of our nightly score over the division's companies that have one; the count is stated.
The key figures cover the whole NACE division 21, not NACE 21100 on its own: there are too few filed annual accounts per five-digit code to compute them separately. Medians over NBB annual accounts, all schema types combined.